Dermatology Times' Weekly Crossword: July 13, 2025

Welcome to Dermatology Times' Weekly Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

6. Whole-body exposure to cold that may reduce inflammation and improve atopic dermatitis symptoms.

8. Type of laser that, when paired with JAK inhibition, improved remission rates in patients with vitiligo.

10. Biologic treatment transforming early intervention strategies in pediatric atopic dermatitis.

11. Acronym for skin of color, where diagnostic blind spots persist in identifying scalp and hair disorders.

14. IL-17A/F inhibitor evaluated not only for psoriasis clearance but also its impact on mental health outcomes.

16. Name brand for newly-available,FDA-approved at-home gel for molluscum contagiosum in patients aged 1 and older.

17. Topical JAK inhibitor shown to have minimal systemic absorption in patients with chronic hand eczema.

Down

1. This biologic demonstrated hand-specific symptom relief in the ADHAND trial for atopic dermatitis.

2. Teledermatology platform spotlighted for improving digital access and patient-clinician relationships.

3. This biotech company reported early psoriasis trial data after unblinding VYN202 following a safety hold.

4. This form of molecular testing is refining melanoma and SCC risk stratification beyond traditional staging.

5. JAK inhibitor used in combination with excimer laser to treat refractory vitiligo and moderate to severe atopic dermatitis.

7. Key measurement tool for vitiligo improvement, used to assess the effects of IL-23 inhibitors like tildrakizumab.

8. Inflammatory skin condition addressed by tralokinumab, delgocitinib, and the NEA Seal of Acceptance program.

9. The FDA recently published over 200 of these decision letters to increase transparency in drug approvals.

12. IL-36 receptor blocker shown to maintain skin clarity between flares in generalized pustular psoriasis.

13. Global dermatology organization that joined with ISD to promote World Skin Health Day 2025.

15. Anti-IL-13 antibody showing high EASI-75 rates in phase 2 trials for moderate to severe atopic dermatitis.

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Weekly Crossword.

Answers from our July 7, 2025 puzzle: [Across: 4 - GEP; 6 - vitiligo; 8 - regenerative; 9 - lebrikizumab; 12 - SCC; 13 - burnout; 14 - OCT; 16 - psoriasis; Down: 1- UTILISE; 2 - delgocitinib; 3 - SkinVive; 5 - pigmentation; 7 - Cardoso; 10 - exosomes; 15 - SPMA]